Atractylenolide III shows neuroprotective effects in preclinical CNS disorder modelsAtractylenolide III shows promise for brain and nerve injuries in lab models

Frontiers in Medicine Published May 29, 2026 DOI ↗ Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider Atractylenolide III as an investigational neuroprotective agent; clinical data are absent.

This narrative review synthesizes preclinical evidence on the neuroprotective effects of Atractylenolide III, a natural compound, across several central nervous system disorders (CNSDs). The review covers studies in models of cognitive impairment, cerebral ischemia/reperfusion injury, depressive disorder, and spinal cord injury. The authors report that Atractylenolide III is effective in these preclinical models, suggesting potential as a therapeutic candidate. However, they emphasize that a systematic summary of its effects on CNSDs is currently lacking. The review does not report specific effect sizes, sample sizes, or safety data, and the authors caution that clinical efficacy, safety profile, pharmacological and toxicological properties, bioavailability, blood-brain barrier penetration, and brain retention remain uncharacterized. While the findings highlight promise, the evidence is limited to preclinical models, and no conclusions can be drawn about human application. Clinicians should interpret these results as preliminary and await further translational research.

Imagine waking up after a stroke or a spinal injury and finding your mind or body struggling to recover. Scientists are looking for new ways to help. Atractylenolide III is one of those new options being studied. This review looked at how it works in preclinical models, which are lab-based tests before humans are involved.

The study found that Atractylenolide III has neuroprotective effects. This means it helps protect brain and nerve cells from damage. It showed positive results in these early tests for conditions like cognitive impairment, cerebral ischemia, and spinal cord injury.

However, there are important limits to keep in mind. This is a summary of effects on central nervous system disorders, and a systematic review of this specific area is currently lacking. We do not yet know how well it works in people or if it is safe for long-term use. These early findings highlight its promise as a therapeutic candidate, but we must wait for more data.

What this means for you:

Atractylenolide III shows promise in lab models for brain and nerve injuries, but human trials are needed.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedMay 2026

View Original Abstract ↓

Central nervous system disorders (CNSDs) are a leading cause of global mortality and disability, yet treatment options remain limited. Natural compounds derived from traditional Chinese herbs constitute a vital resource for discovering novel neuroprotective agents. Atractylenolide III (ATL-III), a sesquiterpene lactone isolated from the spleen-fortifying herb Atractylodes macrocephala Koidz., exhibits neuroprotective properties and possesses the ability to cross the blood-brain barrier (BBB). However, a systematic summary of its effects on CNSDs is currently lacking. This review therefore aimed to comprehensively summarize the therapeutic effects and underlying mechanisms of ATL-III against various CNSDs, and to provide insights for future clinical translation. A systematic literature search was conducted using PubMed, Web of Science, Google Scholar, China National Knowledge Infrastructure, and Wanfang Database for studies published or available online between 1 January 2016, and 31 December 2025. The compiled evidence demonstrates that ATL-III is effective in preclinical models of cognitive impairment, cerebral ischemia/reperfusion injury, depressive disorder, and spinal cord injury. Its neuroprotective mechanisms are multifaceted, involving the enhancement of neurotransmitter storage, reduction of neurotoxic protein accumulation, and exerting anti-apoptotic, anti-inflammatory, antioxidant, and autophagy-regulating effects, alongside BBB repair. In conclusion, ATL-III exerts broad neuroprotective effects through multi-target mechanisms, highlighting its promise as a therapeutic candidate for CNSDs. To realize this potential, key future efforts should include: (1) conducting definitive clinical trials to establish its efficacy and safety profile; (2) comprehensively elucidating its pharmacological and toxicological properties; and (3) developing novel delivery strategies to enhance its bioavailability, BBB penetration, and brain retention.

Atractylenolide III shows neuroprotective effects in preclinical CNS disorder modelsAtractylenolide III shows promise for brain and nerve injuries in lab models

Study Details

Mazdutide monotherapy reduces HbA1c and promotes weight loss in Chinese adults with type 2 diabetes over 48 weeks

New Drug Lowers Sugar and Shrinks Weight in Diabetes

Clinical research that matters. Delivered to your inbox.

Atractylenolide III shows neuroprotective effects in preclinical CNS disorder modelsAtractylenolide III shows promise for brain and nerve injuries in lab models

More on Mild Cognitive Impairment

Study Details

Mazdutide monotherapy reduces HbA1c and promotes weight loss in Chinese adults with type 2 diabetes over 48 weeks

New Drug Lowers Sugar and Shrinks Weight in Diabetes

Clinical research that matters. Delivered to your inbox.

Related in Drug Pipeline

From Other Specialties